Recent Strategies for the Catalytic Asymmetric Synthesis of Hydrogenated Pyridazines

The pyridazine scaffold has a distinctive physicochemical profile, characterized by the ability to engage in dual hydrogen bonding, a large dipole moment influencing pi‐stacking interactions, and a unique basicity, which is essential for controlling its interactions with biological targets. Consequently, the pyridazine nucleus has emerged as a privileged motif that is present in several FDA‐approved therapeutics, including inodilator Levosimendan, ACE inhibitor Cilazapril, and PARP inhibitor Talazoparib. Asymmetric catalysis, a cornerstone of contemporary synthetic methodology, provides tools for synthesizing enantiopure chiral pyridazines and their corresponding oxidized derivatives. The synthetic utility and pharmacological relevance of the scaffold have catalyzed significant interest in organic chemists, resulting in a growing suite of enantioselective catalytic protocols. The rapid diversification of these methodologies warrants a systematic review of the reported strategies for asymmetric induction.